Focused innovation with the patient at the center of our business.
Perspective Therapeutics, Inc., is a clinical stage, radiopharmaceutical development company that is pioneering advanced treatments for cancers. The Company’s proprietary technology utilizes the alpha emitting isotope, Pb-212, to deliver powerful radiation specifically to cancer cells via targeting peptides. Complementarily, the Company is developing imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables visualization and treatment of specific tumors, which has the potential to improve efficacy and minimize toxicity associated with many other types of cancer treatments.
Our Focus
Our focus is on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies so our targeted medical doses are delivered directly to the tumor site. We believe radiation should spare healthy tissues and be delivered from the inside out.
Our Approach
We are committed to identifying ways to best deliver therapies for patients and their medical needs and believe in a targeted personalized approach to treating each patient’s cancer. We develop treatments that are delivered exactly where the clinician wants.
Strong Partnerships
Our partnerships and trials with globally recognized medical institutions and pharmaceutical companies are reflective of our goal to be at the forefront of progress and innovation. All of this is grounded in our continual pursuit of meeting and exceeding patient needs.
Our Technology
Our Radioisotope technology treats tumors on a cellular level when patients are most likely in early stages of cancers. We use proprietary targeting peptides to diagnose tumors, and then deliver Alpha-Particle Radiopharmaceuticals to attack them on a molecular level when the cancer has spread to other sites in the body.
The Combination of a Therapeutic and a Diagnostic.
Theranostics enable the ability to see a specific tumor and then treat it.
Using proprietary, specialized targeting peptides, we are able to diagnose and then deliver our powerful alpha-particle radiotherapy directly to the tumor. Utilizing a radioactive imaging agent, Pb-203, connected to a specific targeting peptide, we have the ability to diagnose the tumor. Following diagnosis, we link our alpha-particle radioactive isotope, Pb-212, to the same targeting peptide to treat and potentially kill the tumor. This two-step, personalized medicine approach offers the ability to understand which patients may respond to our therapy and potentially improve efficacy while minimizing toxicity associated with many other types of cancer treatments
Our leading Pb-212-based alpha-particle radiotherapies are designed to deliver powerful alpha radiation specifically to cancer cells utilizing specialized targeting peptides. Perspective Therapeutics is also developing complementary imaging diagnostics that utilize the same targeting peptide for the purpose of personalizing treatment and optimizing patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.
“Preclinical and clinical data associated with this new radiopharmaceutical demonstrates significant potential to help our NET patients. We appreciate the professionalism and scientific strength of the Viewpoint (Perspective Therapeutics) team.”
Dr. Ishita B Sen MBBS
Director and Head of Nuclear Medicine, Fortis Hospital, New Delhi.
